The immunological and epidemiological efficiency of hepatitis B vaccination: Multicenter study results


Shaginyan V.R., Gural A.L., Sergeeva T.A., Maksimenok E.V., Myshko O.V., Sadkova A.B.

L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Sciences of Ukraine, Kiev
Objective. To define the indicators of immune response to hepatitis B (HB) vaccination in different periods after immunization and to evaluate its epidemiological efficiency from the detection rates of HBV infection markers in vaccinated and unvaccinated children from different regions of Ukraine.
Subjects and methods. 1586 serum samples obtained from HB vaccinated and unvaccinated children in different regions of Ukraine were examined. Enzyme immunoassay was used to measure HBsAg, anti-НВс, and анти-HBs level.
Results. Among the vaccinated children, there were a large number of negative anti-HBs cases (46.7%) with the highest proportion in the 10–14-year-old group (57.9%). There was evidence supporting the comparable immunological efficiency of two- and three-dose vaccination. The HB vaccination initiated in infants above 1 year of age was shown to be more immunological efficient than neonatal immunization. The epidemiological vaccination efficiency coefficient was 71.2%. There were data on equal HBV infection rates in HB vaccinated and unvaccinated children aged 10–14 years (3.7 and 2.0%, respectively). In the vaccinated children, the presence of HBV infection markers was accompanied by the absence of a protective anti-HBs level.
Conclusion. The results of the multicenter study conducted in Ukraine suggest that HB vaccination has displayed a good epidemiological efficiency as a whole. They show the need for further investigations to determine when to initiate vaccination in infants with no risk of perinatal infection and whether booster immunization is expedient in the low HB prevalence regions.

Literature



  1. Hepatitis B vaccine: WHO position paper. Wkly Epidemiol. Rec. 2009; 84(40): 405–420.

  2. Robotin M.C. Hepatitis B prevention and control: Lessons from the East and the West. World J. Hepatol. 2011; 3(2): 31–37.

  3. Ahmed F., Foster G.R. Global hepatitis, migration and its impact on Western healthcare. Gut 2010; 59(8): 1009–1011.

  4. Chu J.J., Wörmann T., Popp J. et al. Changing epidemiology of Hepatitis B and migration – a comparison of six Northern and North-Western European countries. Eur. J. Public. Health. 2012; 1–6. http://eurpub.oxfordjournals.org/ просмотрено 15.02.2013

  5. Chen D.S. Toward elimination and eradication of hepatitis B. J. Gastroenterol. Hepatol. 2010; 25: 19–25.

  6. Viral Hepatitis. 2012; 20(2): 28 р. http://www.vhpb.org/files/html/Meetings_and_publications/Premeeting_documents/backgrounddocljubjlana.pdf

  7. van der Sande M., Waight Р.А., Mendy М. et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE. 2007; 2(1): e753.

  8. Pokorska-Lis M., Marczyńska M. [Are teenagers immunized in infancy still protected against hepatitis B?]. Przegl Lek. 2010; 67(1): 13–17. [In Polish].

  9. Zhu CL, Liu P, Chen T. et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011; 29(44):7835–7841.

  10. Chau-Ting Yeh, Ming-Wei Lai. Eliminating hepatitis B virus through neonatal vaccination: Can we make it? J. Hepatol. 2012; 57: 484–485.

  11. Shahmoradi S, Yahyapour Y, Mahmoodi M. et al. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J. Hepatol. 2012; 57: 515–521.

  12. Aghakhani A, Banifazl M, Izadi N. et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World J. Pediatr. 2011; 7(4): 358–360.

  13. Cherkasskiy B.L. Risk v epidemiologii [The risk in epidemiology]. Moscow: Prakticheskaya meditsina, 2007. 480 p. (In Russ.)

  14. Briko N.I. Otsenka kachestva i effektivnosti immunoprofilaktiki [Evaluation of the quality and effectiveness of immunization]. Lechashhij vrach 2012; 12. http://www.lvrach.ru/2012/10/15435557 (In Russ.).

  15. Antomonov M.Yu. Matematicheskaya obrabotka i analiz mediko-biologicheskih dannyih [Mathematical processing and analysis of biomedical data]. Kyiv, 2006. 558 с.

  16. Lapach S.N., Tschubenko A.V., Babich P.N. Statisticheskie metodyi v mediko-biologicheskih issledovaniyah s ispolzovaniem Excel [Statistical methods in biomedical studies using Excel]. Kyiv: Morion, 2000. 320 p.

  17. Schillie S.F., Murphy T.V. Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review. Vaccine 2012; 12.012. [Epub ahead of print].

  18. Stroffolini T, Guadagnino V, Caroleo B et al. Long-term immunogenicity of hepatitis B vaccination in children and adolescents in a southern Italian town. Infection 2012; 40(3): 299–302.

  19. But D.Y., Lai C.L., Lim W.L. et al. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26(51): 6587–6591.

  20. Van Damme P., Moiseeva A., Marichev I. et al. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11–15 years: a randomised controlled study. BMC Infect. Dis. 2010; 20.10.357. http://www.biomedcentral.com/1471–2334/10/357

  21. Hepatitis B vaccine. WHO position paper. Wkly Еpidemiol. Rec. 2004; 28(79): 253–264.


About the Autors


Shaginyan Valeria Robertovna, MD; Leading Researcher, Laboratory for Epidemiology of Parenteral Viral Hepatitis and HIV Infection, L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Sciences of Ukraine
Address: 5, N. Amosov St., Kiev 03680, Ukraine
Telephone: +038 (044) 275-37-11
E-mail: shaginianvaleria@mail.ru


Similar Articles


Бионика Медиа